Cidara Theraptcs Stock Price, News & Analysis

Cidara Therapeutics (Nasdaq: CDTX) announced two upcoming oral presentations at the International Society for Respiratory Viruses (ISRV) conference in Singapore, September 17-20, 2025. The presentations will feature clinical and preclinical data for their drug candidate CD388.

The first presentation is a late-breaking abstract showcasing Phase 2b clinical trial results (NAVIGATE study) evaluating CD388's efficacy and safety for influenza prevention in healthy adults. The second presentation will discuss preclinical data demonstrating CD388's protective effects against H5N1 influenza virus in ferret models.

Cidara Therapeutics (Nasdaq: CDTX) reported significant Q2 2025 developments, highlighted by positive Phase 2b NAVIGATE trial results for CD388, their influenza prevention drug. The trial met all primary and secondary endpoints, with the highest dose (450mg) showing 76.1% protection against symptomatic influenza over 24 weeks.

The company substantially strengthened its financial position by closing an upsized public offering of $402.5 million, pricing 9.1 million shares at $44.00 each. As of June 30, 2025, Cidara reported cash and equivalents of $516.9 million. The company has submitted an End of Phase 2 meeting request to the FDA and plans to initiate Phase 3 trials by spring 2026.

Q2 financial results showed increased R&D expenses of $24.8 million, up from $6.7 million in Q2 2024, primarily due to CD388 development. The company reported a net loss of $25.7 million for Q2 2025, compared to $91.2 million in Q2 2024.

Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company specializing in drug-Fc conjugate (DFC) immunotherapies through its Cloudbreak® platform, has scheduled its second quarter 2025 financial results announcement for August 7, 2025.

The company will release its financial results and operational highlights after U.S. market close, followed by a conference call and webcast at 5:00 PM Eastern Time. Investors can access the call via U.S. toll-free (1-844-825-9789) or international (1-412-317-5180) numbers using Conference ID 10200740.

Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company focused on developing drug-Fc conjugate therapeutics through its Cloudbreak® platform, has announced new equity grants to two employees. The Compensation Committee approved non-qualified stock options and restricted stock units (RSUs) totaling 12,100 shares of common stock under the company's 2020 Inducement Incentive Plan.

The stock options were granted at an exercise price of $48.71 per share, matching Cidara's closing price on June 30, 2025. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. The RSUs will vest in four equal annual installments on specified quarterly vesting dates.

Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company focused on drug-Fc conjugate therapeutics through its Cloudbreak® platform, has announced its inclusion in both the Russell 2000® and Russell 3000® Indexes. The Russell 3000 Index represents the 3,000 largest U.S. companies by market cap, covering approximately 98% of the investable U.S. equity market, while the Russell 2000 Index focuses on the small-cap segment.

CEO Jeffrey Stein highlighted this milestone alongside other recent company achievements, including positive Phase 2b NAVIGATE trial results and a successful $400 million financing round. The index inclusion is expected to increase Cidara's visibility among institutional investors.

Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company, has successfully completed an upsized public offering of 9,147,727 shares of common stock at $44.00 per share. The offering includes the full exercise of underwriters' option to purchase an additional 1,193,181 shares. The company raised gross proceeds of $402.5 million before deducting underwriting discounts and commissions.

The offering was managed by prominent financial institutions including J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor as joint book-running managers. The shares were offered through a shelf registration statement on Form S-3 that was declared effective by the SEC on May 15, 2025.

Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company specializing in drug-Fc conjugate therapeutics through its Cloudbreak® platform, has announced the pricing of an upsized public offering. The company will offer 7,954,546 shares at $44.00 per share, expecting to raise $350.0 million in gross proceeds before deductions.

The offering includes a 30-day option for underwriters to purchase up to 1,193,181 additional shares at the public offering price. The offering, expected to close on June 26, 2025, is being managed by J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor as joint book-running managers.

Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company specializing in drug-Fc conjugate therapeutics through its Cloudbreak® platform, has announced plans for a $250.0 million underwritten public offering of common stock. The company intends to grant underwriters a 30-day option to purchase up to an additional 15% of shares.

The offering will be managed by joint book-runners J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor. The offering is being made through a shelf registration statement on Form S-3 that was declared effective by the SEC on May 15, 2025.

Cidara Therapeutics (NASDAQ: CDTX) announced positive topline results from its Phase 2b NAVIGATE trial evaluating CD388, a novel drug-Fc conjugate for preventing seasonal influenza. The trial demonstrated significant protection efficacy across all dose groups, with a single dose providing up to 76% protection over 24 weeks compared to placebo. The 450mg dose showed the highest efficacy (76.1%), followed by 300mg (61.3%) and 150mg (57.7%). The study met its primary endpoint and all secondary endpoints, including efficacy at different temperature thresholds and protection lasting up to 28 weeks. CD388 was well-tolerated across all doses with no safety concerns or drug-related serious adverse events. The company has submitted an end of Phase 2 meeting request to the FDA to discuss Phase 3 trial design.